ImmunoGen Announces Conference Call To Discuss Its Fourth Quarter And Fiscal Year 2016 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, August 4, 2016, to discuss ImmunoGen's financial results for the three-month period and fiscal year ended June 30, 2016. Management also will provide an update on mirvetuximab soravtansine and other ImmunoGen product programs.